EJS-4 The impact of COVID-19 pandemic on the new drug development and exploration of new trial design

por Yamamoto, Noboru
Publicado 2022

Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3 Weeks in Japanese Patients with Solid Tumors

por Yamada, Kazuhiko, Yamamoto, Noboru, Yamada, Yasuhide, Mukohara, Toru, Minami, Hironobu, Tamura, Tomohide
Publicado 2010

Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China

por Mizuno, Takaaki, Katsuya, Yuki, Sato, Jun, Koyama, Takafumi, Shimizu, Toshio, Yamamoto, Noboru
Publicado 2022

Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors

por Yamamoto, Noboru, Yamada, Yasuhide, Fujiwara, Yutaka, Yamada, Kazuhiko, Fujisaka, Yasuhito, Shimizu, Toshio, Tamura, Tomohide
Publicado 2009

Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors

por Murakami, Haruyasu, Ueda, Yutaka, Shimoyama, Tatsu, Yamamoto, Noboru, Yamada, Yasuhide, Arioka, Hitoshi, Tamura, Tomohide
Publicado 2010

Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid t...

por Ueda, Yutaka, Shimoyama, Tatsu, Murakami, Haruyasu, Yamamoto, Noboru, Yamada, Yasuhide, Arioka, Hitoshi, Tamura, Tomohide
Publicado 2010

Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors

por Wakui, Hiroshi, Yamamoto, Noboru, Nakamichi, Shinji, Tamura, Yousuke, Nokihara, Hiroshi, Yamada, Yasuhide, Tamura, Tomohide
Publicado 2014

Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors

por Doi, Toshihiko, Matsubara, Nobuaki, Kawai, Akira, Naka, Norifumi, Takahashi, Shunji, Uemura, Hiroji, Yamamoto, Noboru
Publicado 2019

Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study

por Kondo, Shunsuke, Iwasa, Satoru, Koyama, Takafumi, Fujita, Tomoko, Sugibayashi, Ko, Murayama, Kosho, Yamamoto, Noboru
Publicado 2022

Prevalence of psychological distress, quality of life, and satisfaction among patients and family members following comprehensive genomic profiling testing: Protocol of the Quality...

por Nishino, Makoto, Fujimori, Maiko, Koyama, Takafumi, Hirata, Makoto, Tanabe, Noriko, Shimizu, Toshio, Yamamoto, Noboru, Uchitomi, Yosuke
Publicado 2023

Alveolar Soft Part Sarcoma: A Single-Center 26-Patient Case Series and Review of the Literature

por Ogura, Koichi, Beppu, Yasuo, Chuman, Hirokazu, Yoshida, Akihiko, Yamamoto, Noboru, Sumi, Minako, Kawano, Hirotaka, Kawai, Akira
Publicado 2012

A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells

por Yamashita, Makiko, Kitano, Shigehisa, Aikawa, Hiroaki, Kuchiba, Aya, Hayashi, Mitsuhiro, Yamamoto, Noboru, Tamura, Kenji, Hamada, Akinobu
Publicado 2016

Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors

por Mizugaki, Hidenori, Yamamoto, Noboru, Murakami, Haruyasu, Kenmotsu, Hirotsugu, Fujiwara, Yutaka, Ishida, Yoshimasa, Kawakami, Tomohisa, Takahashi, Toshiaki
Publicado 2016

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan

por Shimomura, Akihiko, Kondo, Shunsuke, Kobayashi, Noriko, Iwasa, Satoru, Kitano, Shigehisa, Tamura, Kenji, Fujiwara, Yutaka, Yamamoto, Noboru
Publicado 2017

Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies

por Tanaka, Midori, Horinouchi, Hidehito, Goto, Yasushi, Kanda, Shintaro, Fujiwara, Yutaka, Nokihara, Hiroshi, Yamamoto, Noboru, Ohe, Yuichiro
Publicado 2018

Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials

por Koyama, Takafumi, Kondo, Shunsuke, Shimizu, Toshio, Fujiwara, Yutaka, Morizane, Chigusa, Sakamoto, Yasunari, Okusaka, Takuji, Yamamoto, Noboru
Publicado 2019

Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials

por Fujiwara, Yutaka, Kuchiba, Aya, Koyama, Takafumi, Machida, Ryunosuke, Shimomura, Akihiko, Kitano, Shigehisa, Shimizu, Toshio, Yamamoto, Noboru
Publicado 2020

CD20(+) tumor‐infiltrating immune cells and CD204(+) M2 macrophages are associated with prognosis in thymic carcinoma

por Sato, Jun, Kitano, Shigehisa, Motoi, Noriko, Ino, Yoshinori, Yamamoto, Noboru, Watanabe, Shunichi, Ohe, Yuichiro, Hiraoka, Nobuyoshi
Publicado 2020

The optimal duration of antimicrobial therapy for lower respiratory tract infection in patients with neuromuscular disorders based on a clone library analysis of the bacterial 16S...

por Kawamura, Masaru, Hoshina, Takayuki, Ogawa, Masato, Yamamoto, Noboru, Haro, Kaoru, Kumadaki, Tokiko, Fukuda, Kazumasa, Kusuhara, Koichi
Publicado 2020

A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors

por Nokihara, Hiroshi, Yamamoto, Noboru, Yamada, Yasuhide, Yamada, Kazuhiko, Hirata, Taizo, Goto, Yasushi, Tanioka, Maki, Ikeda, Yoko, Tamura, Tomohide
Publicado 2012